What is Salignostics?
Salignostics operates at the intersection of biotechnology and consumer health, specializing in advanced saliva-based diagnostic platforms. By leveraging proprietary saliva concentrator technology, the firm effectively addresses the inherent challenges of biomarker detection, providing a robust alternative to traditional blood-based or invasive testing methods. The company's flagship innovation, Salistick, represents a significant breakthrough as the first CE-approved saliva-based pregnancy test, demonstrating the scalability and regulatory viability of their core technology. Their market position is defined by a commitment to accessibility, serving diverse sectors ranging from professional healthcare providers and clinical laboratories to the rapidly expanding home-testing market. Through this strategic focus, Salignostics is effectively disrupting the diagnostic status quo, offering a user-friendly, cost-effective, and highly reliable testing ecosystem.
How much funding has Salignostics raised?
Salignostics has raised a total of $8M across 1 funding round:
Series A
$8M
Series A (2022): $8M with participation from Avigdor Orlinsky
Key Investors in Salignostics
Avigdor Orlinsky
A private investor with a focus on supporting high-growth medical technology and diagnostic innovation.
What's next for Salignostics?
With the recent capital injection, Salignostics is poised to transition from its current development phase into a broader commercial scaling strategy. The company is expected to prioritize the expansion of its manufacturing capabilities and the global distribution of its diagnostic portfolio. Future growth will likely center on diversifying its product pipeline to include additional biomarker assays, further cementing its authority in the non-invasive diagnostics sector. As the healthcare industry continues to shift toward decentralized and patient-centric care, Salignostics is strategically aligned to capture significant market share by providing rapid, actionable insights that empower both clinicians and consumers. The firm's ability to maintain high diagnostic standards while simplifying the testing process will be critical as it navigates the complexities of international regulatory environments and competitive market dynamics.
See full Salignostics company page
